No abstract available
Publication types
-
Editorial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD20 / analysis
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Chemotherapy, Adjuvant
-
Disease-Free Survival
-
Evidence-Based Medicine
-
Humans
-
Lymphoma, B-Cell / drug therapy
-
Lymphoma, B-Cell / immunology
-
Lymphoma, B-Cell / pathology
-
Lymphoma, B-Cell / radiotherapy*
-
Neoplasm Staging
-
Radioimmunotherapy*
-
Radiotherapy, Adjuvant
-
Research Design
-
Time Factors
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antigens, CD20
-
ibritumomab tiuxetan